|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0087111,
umls-concept:C0205177,
umls-concept:C0205460,
umls-concept:C0282460,
umls-concept:C0442027,
umls-concept:C0450442,
umls-concept:C1171350,
umls-concept:C1553423,
umls-concept:C1698931
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-31
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1529-0131
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 by the American College of Rheumatology.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
337-45
|
|
pubmed:dateRevised |
2011-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:21279990-Administration, Oral,
pubmed-meshheading:21279990-Adolescent,
pubmed-meshheading:21279990-Adult,
pubmed-meshheading:21279990-Aged,
pubmed-meshheading:21279990-Aged, 80 and over,
pubmed-meshheading:21279990-Antirheumatic Agents,
pubmed-meshheading:21279990-Arthritis, Rheumatoid,
pubmed-meshheading:21279990-Dose-Response Relationship, Drug,
pubmed-meshheading:21279990-Drug Resistance,
pubmed-meshheading:21279990-Enzyme Inhibitors,
pubmed-meshheading:21279990-Female,
pubmed-meshheading:21279990-Health Status,
pubmed-meshheading:21279990-Humans,
pubmed-meshheading:21279990-Immunologic Factors,
pubmed-meshheading:21279990-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:21279990-Joints,
pubmed-meshheading:21279990-Male,
pubmed-meshheading:21279990-Middle Aged,
pubmed-meshheading:21279990-Oxazines,
pubmed-meshheading:21279990-Prodrugs,
pubmed-meshheading:21279990-Protein-Tyrosine Kinases,
pubmed-meshheading:21279990-Pyridines,
pubmed-meshheading:21279990-Severity of Illness Index,
pubmed-meshheading:21279990-Treatment Outcome,
pubmed-meshheading:21279990-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
|
|
pubmed:affiliation |
Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA. genovese@stanford.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
